Cargando…

Visual Outcomes and Prognostic Factors of Large Submacular Hemorrhages Secondary to Polypoidal Choroidal Vasculopathy

PURPOSE: Patients with polypoidal choroidal vasculopathy (PCV) may develop large submacular hemorrhages (SMHs), which may result in severe visual loss. This study was performed to determine the visual outcomes and prognostic factors of large SMHs secondary to PCV. PATIENTS AND METHODS: We retrospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuo, Yu, Haruta, Masatoshi, Ishibashi, Yumi, Ishibashi, Koki, Furushima, Kei, Kato, Nobuhiro, Murotani, Kenta, Yoshida, Shigeo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403222/
https://www.ncbi.nlm.nih.gov/pubmed/34465976
http://dx.doi.org/10.2147/OPTH.S327138
_version_ 1783745958551486464
author Matsuo, Yu
Haruta, Masatoshi
Ishibashi, Yumi
Ishibashi, Koki
Furushima, Kei
Kato, Nobuhiro
Murotani, Kenta
Yoshida, Shigeo
author_facet Matsuo, Yu
Haruta, Masatoshi
Ishibashi, Yumi
Ishibashi, Koki
Furushima, Kei
Kato, Nobuhiro
Murotani, Kenta
Yoshida, Shigeo
author_sort Matsuo, Yu
collection PubMed
description PURPOSE: Patients with polypoidal choroidal vasculopathy (PCV) may develop large submacular hemorrhages (SMHs), which may result in severe visual loss. This study was performed to determine the visual outcomes and prognostic factors of large SMHs secondary to PCV. PATIENTS AND METHODS: We retrospectively reviewed the medical records of patients diagnosed with PCV who developed a large SMH. The best-corrected visual acuity (BCVA) data were collected at the SMH development, 1 month, 1 year after the SMH development, and at the final visit. Patients’ medical information also were collected and included age, gender, systemic hypertension, current regular use of an anticoagulant or antiplatelet medication, the initial area of the SMH, breakthrough vitreous hemorrhage, ocular treatment, and fellow eye status. Univariate and multiple regression analyses were performed to determine the prognostic factors for the BCVA 1 year after the development of large SMHs. RESULTS: Thirty eyes of 29 patients were included in this study. The mean area of the SMHs at the development was 17.0 disc areas. The mean follow-up period after the development of SMHs was 53.5 months. The mean BCVA at the development, 1 month, and 1 year after the development, and at the final visit were 20/151, 20/263, 20/138, and 20/152, respectively. Multiple regression analyses indicated that a SMH 20 disc areas or larger was a significant negative factor, and the BCVA 1 month after the development was a significant positive factor affecting the BCVA 1 year after the development of large SMHs. CONCLUSION: The increase in the initial area of SMH was correlated inversely with the BCVA 1 year after the development of SMH. The BCVA 1 month after the development may predict the BCVA 1 year after the development of a large SMH.
format Online
Article
Text
id pubmed-8403222
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-84032222021-08-30 Visual Outcomes and Prognostic Factors of Large Submacular Hemorrhages Secondary to Polypoidal Choroidal Vasculopathy Matsuo, Yu Haruta, Masatoshi Ishibashi, Yumi Ishibashi, Koki Furushima, Kei Kato, Nobuhiro Murotani, Kenta Yoshida, Shigeo Clin Ophthalmol Original Research PURPOSE: Patients with polypoidal choroidal vasculopathy (PCV) may develop large submacular hemorrhages (SMHs), which may result in severe visual loss. This study was performed to determine the visual outcomes and prognostic factors of large SMHs secondary to PCV. PATIENTS AND METHODS: We retrospectively reviewed the medical records of patients diagnosed with PCV who developed a large SMH. The best-corrected visual acuity (BCVA) data were collected at the SMH development, 1 month, 1 year after the SMH development, and at the final visit. Patients’ medical information also were collected and included age, gender, systemic hypertension, current regular use of an anticoagulant or antiplatelet medication, the initial area of the SMH, breakthrough vitreous hemorrhage, ocular treatment, and fellow eye status. Univariate and multiple regression analyses were performed to determine the prognostic factors for the BCVA 1 year after the development of large SMHs. RESULTS: Thirty eyes of 29 patients were included in this study. The mean area of the SMHs at the development was 17.0 disc areas. The mean follow-up period after the development of SMHs was 53.5 months. The mean BCVA at the development, 1 month, and 1 year after the development, and at the final visit were 20/151, 20/263, 20/138, and 20/152, respectively. Multiple regression analyses indicated that a SMH 20 disc areas or larger was a significant negative factor, and the BCVA 1 month after the development was a significant positive factor affecting the BCVA 1 year after the development of large SMHs. CONCLUSION: The increase in the initial area of SMH was correlated inversely with the BCVA 1 year after the development of SMH. The BCVA 1 month after the development may predict the BCVA 1 year after the development of a large SMH. Dove 2021-08-24 /pmc/articles/PMC8403222/ /pubmed/34465976 http://dx.doi.org/10.2147/OPTH.S327138 Text en © 2021 Matsuo et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Matsuo, Yu
Haruta, Masatoshi
Ishibashi, Yumi
Ishibashi, Koki
Furushima, Kei
Kato, Nobuhiro
Murotani, Kenta
Yoshida, Shigeo
Visual Outcomes and Prognostic Factors of Large Submacular Hemorrhages Secondary to Polypoidal Choroidal Vasculopathy
title Visual Outcomes and Prognostic Factors of Large Submacular Hemorrhages Secondary to Polypoidal Choroidal Vasculopathy
title_full Visual Outcomes and Prognostic Factors of Large Submacular Hemorrhages Secondary to Polypoidal Choroidal Vasculopathy
title_fullStr Visual Outcomes and Prognostic Factors of Large Submacular Hemorrhages Secondary to Polypoidal Choroidal Vasculopathy
title_full_unstemmed Visual Outcomes and Prognostic Factors of Large Submacular Hemorrhages Secondary to Polypoidal Choroidal Vasculopathy
title_short Visual Outcomes and Prognostic Factors of Large Submacular Hemorrhages Secondary to Polypoidal Choroidal Vasculopathy
title_sort visual outcomes and prognostic factors of large submacular hemorrhages secondary to polypoidal choroidal vasculopathy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403222/
https://www.ncbi.nlm.nih.gov/pubmed/34465976
http://dx.doi.org/10.2147/OPTH.S327138
work_keys_str_mv AT matsuoyu visualoutcomesandprognosticfactorsoflargesubmacularhemorrhagessecondarytopolypoidalchoroidalvasculopathy
AT harutamasatoshi visualoutcomesandprognosticfactorsoflargesubmacularhemorrhagessecondarytopolypoidalchoroidalvasculopathy
AT ishibashiyumi visualoutcomesandprognosticfactorsoflargesubmacularhemorrhagessecondarytopolypoidalchoroidalvasculopathy
AT ishibashikoki visualoutcomesandprognosticfactorsoflargesubmacularhemorrhagessecondarytopolypoidalchoroidalvasculopathy
AT furushimakei visualoutcomesandprognosticfactorsoflargesubmacularhemorrhagessecondarytopolypoidalchoroidalvasculopathy
AT katonobuhiro visualoutcomesandprognosticfactorsoflargesubmacularhemorrhagessecondarytopolypoidalchoroidalvasculopathy
AT murotanikenta visualoutcomesandprognosticfactorsoflargesubmacularhemorrhagessecondarytopolypoidalchoroidalvasculopathy
AT yoshidashigeo visualoutcomesandprognosticfactorsoflargesubmacularhemorrhagessecondarytopolypoidalchoroidalvasculopathy